心脏机械瓣膜置换术后早期患者抗凝治疗的进展  

Progress of anticoagulant therapy of the patients with mechanical prosthetic valve replacement

作　　者：何帆[1,2] 肖锡俊[1] HE Fan XIAO Xijun(Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, P.R.China Heart Center of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310020, P.R. China)

机构地区：[1]四川大学华西医院心脏大血管外科,成都610041 [2]浙江大学医学院附属邵逸夫医院心脏中心,杭州310020

出　　处：《中国胸心血管外科临床杂志》2017年第11期896-901,共6页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

摘　　要：心脏机械瓣膜置换术后患者需终身抗凝治疗,血栓栓塞及抗凝相关的出血事件仍占机械瓣膜置换术后并发症的绝大部分,大多数则发生于术后半年之内。因此,术后早期的抗凝治疗尤为重要。目前国内外指南主要针对术后远期抗凝治疗方案的制定,对于早期的抗凝治疗方案尚未达成共识。本文结合近年国内外相关抗凝研究,对心脏机械瓣膜置换术后早期患者的抗凝治疗方案的现状进行综述。The patients with mechanical prosthetic valve replacement need anticoagulant therapy for all their life. The incidence of thromboembolism and anticoagulation-related bleeding events still account for major postoperative complications after mechanical heart valve replacement. Most of the complications happen in the first half year after operation. Therefore, early anticoagulation therapy is very important. Of course, so far most guidelines focus stating their opinions on long-term anticoagulant therapy. However, there is no consensus about anticoagulant therapy in the early period of postoperation. In this review, we summarize early anticoagulant therapy of the patients with mechanical heart valve replacement through consulting domestic and abroad relevant research in recent years and give an overview of the present situations of early anticoagulant therapy.

关 键 词：机械瓣置换 早期抗凝 华法林 

分 类 号：R654.2[医药卫生—外科学]